DRAGON-01: IP paclitaxel + IV paclitaxel and S-1 to treat gastric cancer with peritoneal metastasis
The DRAGON-01 study was a Phase III clinical trial that evaluated the use of intraperitoneal (IP) paclitaxel in combination with intravenous (IV) paclitaxel and S-1 to treat gastric cancer with peritoneal metastasis. In this interview, Maheswari Senthil, MD, University of California, Irvine, CA, comments on findings from the DRAGON-01 study, noting that its design, which starts treatment three weeks after surgery and continues for as long as possible, is distinct from other approaches and suggests that patient selection is crucial, particularly in selecting patients with low-burden disease and better biology, to achieve long-term overall survival benefits. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
